Deceptive Conducts before the Patent Office : Challenges for Patent Law and Competition Law
- Nomos Verlagsgesellschaft mbH & Co. KG 2019
- 1 electronic resource (335 p.)
Open Access
In an increasingly harmonized global patent landscape, few issues still distinguish the US patent system as much as its strict–and often criticized–duty of candor and its inequitable conduct doctrine. The EPO and most other countries around the world impose less burdensome disclosure duties upon patent applicants. What is there to learn from the experience in the US? Have these tools resulted in any benefit worth considering? Yet regardless of the disclosure duties imposed upon patent applicants, a deceptive conduct before the Patent Office could lead to unwarranted exclusive rights and have a negative impact on competition. Should antitrust law intervene? Is it a case of sham litigation? This work attempts to answer those questions through a comparative analysis, examining the law and case law in the US and in the EU from both a patent and a competition law perspective and seeking a workable theory of harm.
Creative Commons
English
/doi.org/10.5771/9783748902577 9783748902577
https://doi.org/10.5771/9783748902577 doi
pharmazeutischer Patient irreführendes Verhalten Wettbewerbsrecht Patentanmeldung Patentamt high court Supreme Court inequitable conduct Competition Law kristalline Form Patentrecht Apotex Walker Process tert-Butylaminsalz duty of candor Fraud before the Patent Office Perindopril Scheincharakter AstraZeneca Patent Office Servier LJ Jacob patent law